Progress in the treatment of urethral adenocarcinoma

J Cancer Res Clin Oncol. 2023 Jun;149(6):2693-2698. doi: 10.1007/s00432-022-04481-5. Epub 2022 Nov 21.

Abstract

Background: Urothelial adenocarcinoma (UA) is a rare subtype of primary urothelial carcinoma, which is more common in women and has a poor prognosis. Because of their low incidence, most of the existing literature is based on case reports and there is a lack of comprehensive literature on this type of tumor.

Purpose: This article provides a comprehensive and systematic review of the epidemiology, pathological types, treatment, and prognosis of UA. Especially in the treatment section, we reviewed the various treatment methods including surgery, radiotherapy, chemotherapy, immunotherapy and molecular targeted therapy. This review aims to provide a theoretical basis for the clinical diagnosis and management of UA.

Methods: We reviewed the relevant literature of UA from Pubmed.

Conclusion: There is no standard treatment for UA. Multidisciplinary therapy, including surgery, radiotherapy and chemotherapy, is the current trend. Immunotherapy and molecular targeted therapy will also become viable options for the treatment of UA in future.

Keywords: Epidemiology; Histopathology; Prognosis; Treatment; Urethral adenocarcinoma.

Publication types

  • Systematic Review

MeSH terms

  • Adenocarcinoma* / diagnosis
  • Adenocarcinoma* / therapy
  • Carcinoma, Transitional Cell* / diagnosis
  • Female
  • Humans
  • Prognosis
  • Urethral Neoplasms* / diagnosis
  • Urethral Neoplasms* / therapy
  • Urinary Bladder Neoplasms* / diagnosis